Rhythm Management Group Launches RhythmSynergy™ Technology Platform

Rhythm Management Group, PLLC, has completed the launch of RhythmSynergy™, a powerful new technology platform that leverages machine-learning to efficiently deliver timely and relevant clinical insights for remotely monitored patients with implantable cardiac devices and wearable devices such as blood pressure cuffs, scales, and glucometers.

Recognized as one of the fastest growing companies in North America, Rhythm has more than a decade of experience centralizing and streamlining remote monitoring operational workflows for medical practices and health systems. It applied that knowledge to RhythmSynergy, focusing on features that enhance efficiency such as automated image processing and intuitive reporting.

“With over 10 years in the remote monitoring space and more than 100 years of combined clinical experience, we understand what staff and clinicians need from their remotely monitored data,” said Rhonda Bray, RN, Founder and CEO, Rhythm Management Group. “By extracting that information and providing clinically validated alerts, we accelerate risk identification so users of RhythmSynergy can provide more timely care.”

Key features of RhythmSynergy include:

  • Intuitive clinical and operational reporting
  • Automated image processing
  • Bi-directional EHR integration
  • Mobile and desktop optimized
  • Compliance with industry-leading security standards
  • Secure and scalable infrastructure

By combining clinical expertise and machine-learning technology, RhythmSynergy prioritizes critical information and streamlines review processes. Its sleek, secure design and powerful reporting tools make it easy to review, share, and analyze patient data. By employing automated data processing and real-time alerts, RhythmSynergy enables faster identification of patient health problems so physicians can intervene sooner.

Dr. John P. McKenzie, of Heartbeat Cardiovascular Medical Group, of Glendale, CA, a Rhythm customer, said, “Rhythm’s remote monitoring program, experienced clinical and engagement teams, and RhythmSynergy platform help us deliver better outcomes for patients without burdening our staff. The platform provides the data we need to make critical, informed care decisions, and optimizes data management by helping us achieve 90 percent remote monitoring penetration.”

The RhythmSynergy platform is available for both types of remote monitoring provided by Rhythm Management Group: Cardiac Rhythm Management (CRM) Monitoring, which is for patients with implantable cardiac devices, and Remote Physiologic Monitoring (RPM), which is for patients with smart health tech wireless devices like blood pressure cuffs, scales, and glucometers.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”